Solidseq Comprehensive Panel [275 Genes] Test: Booking, Price, and Results
About Solidseq Comprehensive Panel [275 Genes] Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | Comprehensive Cancer Gene Panel NGS, Hereditary Cancer Multi-Gene Panel, 275 Gene Cancer Sequencing Panel, Comprehensive Tumour Panel |
| Sample Type | FFPE Tissue Block |
| Fasting Required | No |
| Report Time | 30 Days |
| Recommended For | Adults of any gender with a personal or family history suggestive of hereditary cancer; individuals with an existing cancer diagnosis seeking treatment guidance |
| Price | Starting at ₹44,400 |
What Is a Solidseq Comprehensive Panel [275 Genes] Test?
The Solidseq comprehensive panel [275 genes] test is an advanced molecular diagnostic test that analyses 275 cancer-related genes using next-generation sequencing (NGS) technology. It is used to identify inherited gene mutations that increase cancer risk, as well as to guide treatment decisions for individuals already diagnosed with cancer.
The test requires an FFPE (formalin-fixed, paraffin-embedded) tissue block as the sample. It is also known as the comprehensive cancer gene panel NGS, hereditary cancer multi-gene panel, 275-gene cancer sequencing panel, or comprehensive tumour panel.
What Does a Solidseq Comprehensive Panel [275 Genes] Test Measure?
This panel examines 275 genes grouped by their biological role in cancer development, DNA repair, immune response, and drug metabolism. These genes are grouped below by their role in cancer biology:
| Gene Group | Genes Covered | Purpose of Testing |
|---|---|---|
| Hereditary Breast and Ovarian Cancer | BRCA1, BRCA2, PALB2, ATM, CHEK2, BARD1, BRIP1, RAD51C, RAD51D, CDH1, STK11, TP53 | Identify inherited mutations that significantly raise the lifetime risk of breast, ovarian, and related cancers |
| Lynch Syndrome and Mismatch Repair | MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, PMS2, EPCAM | Detect mutations linked to hereditary colorectal, uterine, and other Lynch syndrome-associated cancers |
| Tumour Suppressor Genes | TP53, PTEN, RB1, APC, VHL, STK11, NF1, NF2, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, SUFU, PTCH1, WT1 | Find mutations in genes that normally prevent uncontrolled cell growth |
| Homologous Recombination Repair (HRR) | RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, MRE11, NBN, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, BLM, XRCC2, XRCC3, RECQL4, RPA1 | Detect defects in DNA repair pathways that contribute to cancer development and affect treatment options |
| Chromatin Remodelling and Epigenetic Regulators | ARID1A, ARID1B, ARID2, ARID5B, SMARCA4, SMARCB1, SMAD2, SMAD4, KMT2A, KMT2B, KMT2C, KMT2D, SETD2, CREBBP, EP300, KDM5C, KDM6A, ASXL1, ASXL2, DAXX, ATRX, PBRM1, BCOR, PHF6, HDAC2, HDAC9, NCOR1 | Detect alterations in genes controlling how DNA is packaged and how genes are switched on or off, influencing tumour growth |
| Cell Cycle Regulators | CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHEK1, CHEK2, CDK12, FBXW7, CALR, PPM1D | Identify mutations that cause cells to divide without normal checkpoints |
| Immune Checkpoint and Immunotherapy Markers | CD274 (PD-L1), PDCD1 (PD-1), PDCD1LG2, CTLA4, CD276, B2M, HLA-A, HLA-B, JAK1, JAK2, JAK3, CIITA, SOCS1, STAT1, TAP1, TAP2, ERAP1, ERAP2, PSMB8, PSMB9, PSMB10, PDIA3, TPP2 | Help predict whether a tumour is likely to respond to immunotherapy drugs |
| Pharmacogenomic Genes | DPYD, CYP2C9, CYP2D6, UGT1A1 | Assess how a patient's body processes specific cancer drugs, helping to optimise dosing and reduce side effects |
| Signalling Pathway Genes | PIK3R1, TSC1, TSC2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, TGFBR2, TCF7L2, AXIN1, AXIN2, RNF43, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK8, GNA13, RASA1, RASA2, LATS1, LATS2, BMPR2, ACVR1B, ACVR2A, ERRFI1, INPP4B | Detect changes in key pathways that drive tumour growth and may be targeted by specific therapies |
| PARP Pathway Genes | PARP1, PARP2, PARP3, PARP4 | Determine eligibility for PARP inhibitor therapy in patients with DNA repair defects |
| Additional Cancer-Associated Genes | ABRAXAS1, ADAMTS12, ADAMTS2, AMER1, ARHGAP35, B2M, BAP1, CASP8, CBFB, CDC73, CDH10, CIC, CSMD3, CTCF, CUL3, CUL4A, CUL4B, CYLD, DDX3X, DICER1, DNMT3A, DOCK3, DSC1, DSC3, ELF3, ENO1, EPHA2, ETV6, FAT1, FAS, FUBP1, GATA3, GPS2, HNF1A, ID3, KEAP1, KLHL13, LARP4B, MEN1, MGA, MTAP, MTUS2, MUTYH, NF1, NF2, POT1, PPP2R2A, PRDM1, PRDM9, PRKAR1A, PTPRT, RB1, RBM10, RNASEH2A, RNASEH2B, RNASEH2C, RPL22, RPL5, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SLX4, SOX9, SPEN, STAG2, TBX3, TET2, TMEM132D, TNFAIP3, TNFRSF14, TP63, USP9X, ZBTB20, ZFHX3, ZMYM3, ZRSR2 | Cover a broad range of tumour types, including haematologic cancers, sarcomas, and rare hereditary syndromes |
Why Is a Solidseq Comprehensive Panel [275 Genes] Test Done?
This test is ordered when a doctor needs to assess inherited cancer risk or guide treatment planning. It covers a wide range of hereditary cancer syndromes and therapy-relevant gene alterations.
Common Symptoms and Indications That May Require This Test
The following situations commonly lead a doctor to recommend this test:
- Cancer diagnosed at an unusually young age
- Multiple different cancers occurring in the same person
- A strong family history of the same or related cancers across multiple relatives
- Unusual or rare cancer presentation that suggests a hereditary cause
- A known hereditary cancer syndrome in the family
- Need for targeted therapy or immunotherapy guidance in an existing cancer diagnosis
Conditions This Test Can Help Detect
This panel can help identify mutations associated with a range of hereditary cancer syndromes and treatment-relevant conditions:
- Hereditary breast and ovarian cancer syndrome (BRCA1 and BRCA2 mutations)
- Lynch syndrome, associated with high lifetime risk of colorectal and uterine cancers
- Li-Fraumeni syndrome (TP53 mutations)
- Familial adenomatous polyposis (APC mutations), linked to a near-certain risk of colorectal cancer without intervention
- Cowden syndrome (PTEN mutations)
- Fanconi anaemia, a disorder of impaired DNA repair
- Hereditary paraganglioma-phaeochromocytoma syndrome (SDH gene mutations)
- Von Hippel-Lindau syndrome (VHL mutations)
- Multiple endocrine neoplasia (MEN1 mutations)
How to Prepare and What to Expect
The Solidseq comprehensive panel [275 genes] test procedure is straightforward and requires no special preparation on your part.
Do You Need to Fast?
No fasting is required for this test. You may eat and drink normally before sample collection. Always follow any specific instructions provided by your doctor.
Practical Tips Before Your Test
The following steps will help ensure a smooth sample submission:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test
- Carry documentation of your family cancer history, including the types of cancer and ages of diagnosis in relatives
- Inform the laboratory if you have received a blood transfusion recently; a gap of at least two weeks is advisable before testing
- Continue taking your regular medications unless your doctor advises otherwise
- Consider pre-test genetic counselling to understand what the results may mean for you and your family
Step-by-Step Procedure
The sample for this test is an FFPE (formalin-fixed, paraffin-embedded) tissue block, a preserved tissue specimen from a prior biopsy or surgery. Here is what the process involves:
- Your treating doctor or surgeon arranges for the relevant stored tissue block to be retrieved from the pathology archive.
- The tissue block is labelled with your patient details and sent to the Lupin Diagnostics molecular laboratory in appropriate packaging.
- The block is transported at ambient temperature (18 to 28°C) and must be handled carefully to preserve sample quality.
- In the laboratory, DNA is extracted from the tissue and prepared for sequencing.
- Next-generation sequencing (NGS) is performed to read and analyse all 275 genes in the panel.
- Molecular geneticists and clinical pathologists interpret the findings, and a detailed report is generated within 30 days.
Factors That Can Affect Accuracy
The following factors may influence the quality or accuracy of test results:
- Poor tissue preservation or insufficient DNA quantity in the FFPE block
- Degraded or old tissue samples that may yield low-quality DNA
- Recent blood transfusion (relevant if a blood-based alternative sample is used), which may introduce donor DNA
- Bone marrow transplant recipients may carry donor DNA that interferes with results
- Somatic mosaicism (mutations present in only a fraction of cells) may occasionally be missed if the variant frequency is below the detection threshold
Understanding Your Solidseq Comprehensive Panel [275 Genes] Test Results
Results from this test are qualitative, meaning they are reported as categories rather than numerical values. Your doctor or genetic counsellor will explain what each finding means for your specific situation. The table summarises the key findings:
| Result Category | What It Means |
|---|---|
| Pathogenic or Likely Pathogenic Variant Detected | A disease-causing mutation has been identified in one or more of the tested genes. This may indicate increased hereditary cancer risk or guide treatment decisions. |
| Variant of Uncertain Significance (VUS) | A genetic change has been found, but its clinical significance is not yet known. It may be reclassified as research advances. |
| No Pathogenic Variant Detected | No known disease-causing mutations were found in the 275 genes tested. This does not eliminate all cancer risk. |
Disclaimer: These interpretations are general guidelines. Your doctor or genetic counsellor will interpret your results in the context of your personal health history, family history, and clinical findings. Always consult a qualified healthcare professional for personalised medical advice.
How to Maintain Healthy Levels
While gene mutations cannot be changed, the following lifestyle steps support overall cancer risk reduction:
- Follow a balanced diet rich in vegetables, whole grains, and lean proteins, and maintain a healthy body weight.
- Avoid tobacco in all forms and limit alcohol consumption, both of which are established cancer risk factors.
- Adhere to the cancer screening schedule recommended by your doctor based on your test results and family history.
Lupin Diagnostics Solidseq Comprehensive Panel [275 Genes] Test Price
The Solidseq comprehensive panel [275 genes] test cost at Lupin Diagnostics starts at ₹44,400. This test requires a hospital visit or coordination through your treating doctor for tissue block submission; home collection is not available for this test. The table below shows indicative prices:
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 44400 |
| Pune | 44400 |
| Bangalore | 44400 |
| Chennai | 44400 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps for the Solidseq comprehensive panel [275 genes] test booking:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time, or coordinate with your doctor for tissue block submission.
- Receive your report via email or WhatsApp within 30 days.
Frequently Asked Questions
This test is appropriate for individuals diagnosed with cancer at a young age, those with multiple primary cancers, or anyone with a strong family history of hereditary cancer syndromes. It is also recommended for cancer patients who need information to guide targeted therapy or immunotherapy decisions.
At Lupin Diagnostics, the report is typically delivered within 30 days. The test results are delivered directly via email or WhatsApp.
If a pathogenic variant is identified in your result, first-degree relatives such as parents, siblings, and children may benefit from targeted genetic testing for that specific variant. This is called cascade testing. A genetic counsellor can guide you and your family through this process.
Pre- and post-test genetic counselling is strongly recommended. A genetic counsellor can help you understand what the test covers, what different results mean, and how findings may affect your healthcare decisions and those of your family members.
Yes. The panel includes pharmacogenomic genes such as DPYD, CYP2C9, CYP2D6, and UGT1A1. Variants in these genes can affect how your body processes certain chemotherapy drugs, which may influence treatment dosing and reduce the risk of serious side effects.
No. A negative result means no pathogenic variants were identified in the 275 genes tested. Cancers that arise due to non-inherited (sporadic) causes or mutations in genes not covered by this panel would not be detected. Regular cancer screening as recommended by your doctor remains important regardless of results.
Solidseq Comprehensive Panel [275 Genes] Test: Booking, Price, and Results
